Skip to main content
. Author manuscript; available in PMC: 2010 Jan 14.
Published in final edited form as: Behav Brain Res. 2006 Dec 21;178(2):190–199. doi: 10.1016/j.bbr.2006.12.020

Figure 3.

Figure 3

Mean (±S.E.M.) number of locomotor activity counts during the 30 min session for rats that received treatment with tartaric acid vehicle plus saline vehicle, 0.5 mg/kg haloperidol plus vehicle, and 0.5 mg/kg haloperidol plus various doses of MSX-3 administered systemically. MSX-3 administered to haloperidol-treated rats significantly increased locomotion relative to treatment with haloperidol alone (*p < 0.05). (A) Acute haloperidol treatment (experiment 1; tartaric acid vehicle plus saline vehicle (n = 16), 0.5 mg/kg haloperidol plus vehicle (n = 18), and 0.5 mg/kg haloperidol plus various doses of MSX-3 administered i.p. 0.625 (n = 19), 1.25 (n = 16), 2.5 (n = 16), 5.0 (n = 16), or 10.0 (n = 16) mg/kg MSX-3). (B) Repeated haloperidol treatment (experiment 2; tartaric acid vehicle plus saline vehicle (n = 12), 0.5 mg/kg haloperidol plus vehicle (n = 15), and 0.5 mg/kg haloperidol plus various doses of MSX-3 administered i.p. 0.625 (n = 12), 1.25 (n = 15), 2.5 (n = 15), 5.0 (n = 14), or 10.0 (n = 16) mg/kg MSX-3).